Skip to contentM
Marker Therapeutics, Inc.
M
MRKRMarker Therapeutics, Inc. Released Aug 14, 2015, after the close
10-Q filed Aug 14, 2015, 45 days after period end · 0001424884-15-000124
Q2 2015 · 10-Q
Revenue—
Net Income-$60.22M-$60.22MN/M vs Q2 2014N/M vs Q1 2015 No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marker Therapeutics, Inc. · CIK 1094038 · Engraved from SEC EDGAR
EPS Diluted
-$1.80-$1.80N/M vs Q2 2014N/M vs Q1 2015 Operating Income-$1,138,044— Operating Cash Flowderived-$813,185N/M Filing lag
ended Jun 30, 2015 · filed Aug 14, 2015 · 45 d after period end